Matthew Hageman, MD
Internal Medicine · Belleville, ILNPI 1376540930
Payments from drug & device makers
Across 596 payments — averaging $39.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Butterfly Network, Inc.$15K
- AstraZeneca$2K
- AbbVie$1K
- Boehringer Ingelheim$879
- Lilly USA, LLC$772
- Pfizer$638
- plus $4K from 28 others
What the payments were for
- Consulting fees$14,59861%
- Food & beverage$9,14738%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Butterfly Network, Inc. | 1 | $14,598 |
| AstraZeneca | 113 | $1,835 |
| AbbVie(2 entities) | 67 | $1,004 |
| Boehringer Ingelheim | 54 | $879 |
| Lilly USA, LLC | 46 | $772 |
| Pfizer | 52 | $638 |
| GSK | 43 | $597 |
| Johnson & Johnson | 36 | $568 |
| Novo Nordisk | 43 | $554 |
| Merck | 15 | $254 |
| Amarin Pharma, Inc. | 14 | $217 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $195 |
| Novartis | 11 | $158 |
| Eisai Inc. | 10 | $155 |
| Bayer | 9 | $150 |
| Astellas Pharma US Inc | 10 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $147 |
| Ironwood Pharmaceuticals, Inc | 7 | $118 |
| Sumitomo Pharma America, Inc. | 5 | $113 |
| Sanofi-aventis U.S. LLC | 6 | $93 |
| Amgen | 5 | $90 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Dexcom, Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 4 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $40 |
| Biogen | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 3 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $16 |
| Exact Sciences | 1 | $16 |
How this compares
$23,760 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 275 | $314,723 |
| EliquisApixaban | 223 | $233,580 |
| FarxigaDapagliflozin Propanediol | 216 | $184,859 |
| TrulicityDulaglutide | 41 | $67,632 |
| XareltoRivaroxaban | 76 | $61,024 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $57,636 |
| MyrbetriqMirabegron | 89 | $54,103 |
| OzempicSemaglutide | 41 | $50,366 |
| JanuviaSitagliptin Phosphate | 31 | $39,831 |
| RybelsusSemaglutide | 26 | $37,938 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $32,865 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $28,769 |
| ViberziEluxadoline | 17 | $25,097 |
| TradjentaLinagliptin | 17 | $24,251 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 16 | $21,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $879 | $348,212309 claims |
| PfizerEliquis, Premarin | $638 | $237,920235 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $1,835 | $231,364296 claims |
| Novo NordiskOzempic, Rybelsus | $554 | $88,30367 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $772 | $82,63855 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $597 | $81,688128 claims |
| Johnson & JohnsonXarelto | $568 | $61,02476 claims |
| MerckJanuvia, Belsomra, Dulera | $254 | $56,39871 claims |
| Astellas Pharma US IncMyrbetriq | $150 | $54,10389 claims |
| AbbVieViberzi | $1,004 | $25,09717 claims |
| NovartisEntresto | $158 | $17,66513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Belleville
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.